NEW YORK--(BUSINESS WIRE)--July 5, 2006--OMRIX Biopharmaceuticals, Inc. ("OMRIX" or "The Company") (NASDAQ: OMRI - News), a commercial-stage biopharmaceutical company that develops and markets biosurgical and passive immunotherapy products, announced today that the Company was added to the Russell Microcap(TM) Index effective at the close of U.S. markets on June 30, 2006.
